about
Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato prodrugs.Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?trans,cis,cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer.Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells.The hexacarbonyldicobalt derivative of aspirin acts as a CO-releasing NSAID on malignant mesothelioma cells.Synthesis and biological studies of pyrazolyl-diamine Pt(II) complexes containing polyaromatic DNA-binding groups.Revisiting [PtCl₂(cis-1,4-DACH)]: an underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer.Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.Pt(II) complexes with bidentate and tridentate pyrazolyl-containing chelators: synthesis, structural characterization and biological studies.Synthesis, characterization, structure, molecular modeling studies and biological activity of sterically crowded Pt(II) complexes containing bis(imidazole) ligands.Biological activity of enantiomeric complexes [PtCl(2)L (2)] (L (2) is aromatic bisphosphanes and aromatic diamines).The relevance of polar surface area (PSA) in rationalizing biological properties of several cis-diamminemalonatoplatinum(II) derivatives.The influence of temperature on antiproliferative effects, cellular uptake and DNA platination of the clinically employed Pt(II)-drugs.Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.Cytotoxicity of cis-platinum(II) conjugate models. The effect of chelating arms and leaving groups on cytotoxicity: a quantitative structure-activity relationship approach.Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS).Polyanionic Biopolymers for the Delivery of Pt(II) Cationic Antiproliferative Complexes.How to obtain Pt(iv) complexes suitable for conjugation to nanovectors from the oxidation of [PtCl(terpyridine)].Molecular interaction fields vs. quantum-mechanical-based descriptors in the modelling of lipophilicity of platinum(IV) complexes.Synthesis and characterisation of estrogenic carriers for cytotoxic Pt(II) fragments: biological activity of the resulting complexes.The RP-HPLC measurement and QSPR analysis of logP(o/w) values of several Pt(II) complexes.Cisplatin and valproate released from the bifunctional [Pt(IV)Cl2(NH3)2(valproato)2] antitumor prodrug or from liposome formulations: who does what?An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.Study of the synthesis, antiproliferative properties, and interaction with DNA and polynucleotides of cisplatin-like Pt(II) complexes containing carcinogenic polyaromatic amines.Molecular and statistical modeling of reduction peak potential and lipophilicity of platinum(IV) complexes.Antiproliferative Pt(IV) complexes: synthesis, biological activity, and quantitative structure–activity relationship modelingHybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrugTransition metal carbonyl clusters in biology: A futile or niche research area?Application of microwave-assisted heating to the synthesis of Pt(II) complexesSolvolysis of a Series of Cisplatin-Like Complexes - Comparison between DNA-Biosensor and Conductivity DataStudies on Log Po/w of Quinoxaline di-N-Oxides: A Comparison of RP-HPLC Experimental and Predictive ApproachesThe cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditionsHost–guest inclusion systems of Pt(IV)-bis(benzoato) anticancer drug candidates and cyclodextrinsMetallo-drugs in the treatment of malignant pleural mesotheliomaEvaluation of Platinum-Ethacrynic Acid Conjugates in the Treatment of MesotheliomaOrganometallic compounds in the discovery of new agents against kinetoplastid-caused diseasesPt(IV)/Re(I) Chitosan Conjugates as a Flexible Platform for the Transport of Therapeutic and/or Diagnostic Anticancer Agents
P50
Q38734711-DAF84E70-21DC-4586-8FD4-40AEE7489C61Q38791841-3CA4E29E-CC59-49C7-85E2-74481A249049Q38843429-3AB405E1-D3F3-46C9-9B1B-142D519F88A7Q38867690-6C5DB573-7D48-44FC-A6B3-A7BD45D42845Q38961699-916847D7-15CF-4E12-AAE3-792EFA0CBD79Q39006039-731959A6-41B7-430A-B237-6EB4FF73059EQ39089791-1B3F1EF4-D447-4151-9052-7035C597FBEAQ39093077-9F6EDEA6-E5C7-40DF-8C14-1D99B7AC8AEBQ39265471-43CC07FB-EE97-40C4-AD15-B04707F52F5DQ39315864-F6C76591-B88A-461D-B5AC-EFC49F867956Q39404847-7388C278-627B-407C-B8DE-F5C17C9FC5C4Q39554731-11F6CE5B-994F-4311-BCDD-FD7FB5D55682Q39573364-D2F63EE5-4EE3-45F6-970C-181A4208003EQ39723723-57AC303E-73E4-4137-B17A-7F04E57C0FC2Q39819988-E0B010AF-BB2B-40A2-8C85-47C00FAFA0D6Q40045005-EB252168-739B-4519-B75A-39BB8E063928Q40071039-9B2B185D-1D2D-4356-AF87-4EB04C38B3A4Q40462341-7C3AC3CA-739E-461C-A9E1-817F4DE7D388Q40610067-FA993D84-148E-4C5B-AA69-E65BF5948DD1Q41429967-7F4E7FBA-A157-4A63-B9F2-AF4684FF5176Q46331768-126EE31A-AB48-4816-95E5-BBE6F6CD2D78Q46569102-03E42444-1CD2-406B-A141-69E07C5A6280Q46711805-D467180E-6D8C-4DDC-81F2-E96EE56F6CADQ46985575-0AA36330-0A3A-48D2-9017-746FE598BD42Q48350344-43C28454-30F2-4A17-A74E-DB6CE4CB3DECQ49563999-34991906-DE9A-4982-AE02-189E29E7D42BQ53251531-CCB4AAAF-960C-4230-AD9D-640035F48A1CQ53450886-5CF0C824-75EE-429F-846F-F552AC579B79Q57819324-C0440A52-75B5-4790-B779-4601AF7F8CC2Q58006792-EE746438-EEE3-45D8-AE7F-2A45256E92FCQ58006798-4E62B671-8686-4B35-8728-D9FE3724F1DAQ58064070-950AA9C8-29E2-43C9-AE20-5356DC35FF57Q58486664-5EC081A6-01C1-4847-914F-9C287FAC390AQ58486677-68D2600C-094A-4DF4-A945-3AD7742A1C61Q59034506-955AFC59-F848-4674-98A1-19D8256DADE8Q59034791-5F0BEB72-DA9B-4170-8CCA-99395D0D6083Q59034873-12F11279-7C4F-4B64-8A4C-20401D25B8E9Q59034916-0AD4C8AD-FF06-4D5C-9215-E6C1FE525937Q59229001-76FAC0A3-9786-4ADA-9E24-3EFA9857E20AQ59229015-7815ADCF-5478-4A8E-A0A1-E34A88312102
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Elisabetta Gabano
@ast
Elisabetta Gabano
@en
Elisabetta Gabano
@es
Elisabetta Gabano
@nl
Elisabetta Gabano
@sl
type
label
Elisabetta Gabano
@ast
Elisabetta Gabano
@en
Elisabetta Gabano
@es
Elisabetta Gabano
@nl
Elisabetta Gabano
@sl
prefLabel
Elisabetta Gabano
@ast
Elisabetta Gabano
@en
Elisabetta Gabano
@es
Elisabetta Gabano
@nl
Elisabetta Gabano
@sl
P1053
P-3972-2015
P106
P1153
6507976233
P21
P31
P3829
P496
0000-0002-1181-1955